1. Home
  2. IMMR vs CABA Comparison

IMMR vs CABA Comparison

Compare IMMR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.44

Market Cap

229.4M

Sector

Technology

ML Signal

HOLD

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.39

Market Cap

227.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
CABA
Founded
1993
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
229.4M
227.2M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
IMMR
CABA
Price
$6.44
$2.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
8
Target Price
$12.25
$13.50
AVG Volume (30 Days)
689.7K
2.2M
Earning Date
12-19-2025
11-10-2025
Dividend Yield
4.65%
N/A
EPS Growth
57.07
N/A
EPS
2.04
N/A
Revenue
$163,133,000.00
N/A
Revenue This Year
$988.71
N/A
Revenue Next Year
$109.72
N/A
P/E Ratio
$3.16
N/A
Revenue Growth
338.21
N/A
52 Week Low
$5.65
$0.99
52 Week High
$9.37
$3.67

Technical Indicators

Market Signals
Indicator
IMMR
CABA
Relative Strength Index (RSI) 42.03 48.61
Support Level $6.42 $2.32
Resistance Level $7.09 $2.48
Average True Range (ATR) 0.19 0.14
MACD -0.04 -0.00
Stochastic Oscillator 6.16 17.50

Price Performance

Historical Comparison
IMMR
CABA

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: